Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients.
J Intern Med
; 290(6): 1264-1267, 2021 12.
Article
em En
| MEDLINE
| ID: mdl-34237179
ABSTRACT
BACKGROUND:
It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients.RESULTS:
A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine.CONCLUSION:
This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
4_TD
Base de dados:
MEDLINE
Assunto principal:
RNA Mensageiro
/
Transplantados
/
Imunogenicidade da Vacina
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
Limite:
Humans
Idioma:
En
Revista:
J Intern Med
Ano de publicação:
2021
Tipo de documento:
Article